Philip S.’s Post

Improving #marketaccess is a critical trend for #pharmaceutical companies as we get closer and closer to the new #HTA regulations coming into force in January. As noted by Carnall Farrar, the new UK government's aspiration to make the UK a global life science superpower, is contingent on improving #patientaccess with key considerations on medicine discounts and rising industry rebates long cited as eroding the attractiveness of the UK market to pharmaceutical companies. Give the full article a read here: https://lnkd.in/eWYYRfYH

PwC & EFPIA - European Federation of Pharmaceutical Industries and Associations: “The pharmaceutical industry in Europe' is highly productive compared to the economy as a whole, driven by consistently high levels of research and innovation. The sector contributed €311 billion Gross Value Added (GVA) and 2.3 million jobs to the EU-27 economy in 2022.” 📌 The report calculates EFPIA’s economic footprint in Europe. Imagine the impact of the entire pharmaceutical ecosystem, including generics and biosimilars. 📌 Regulatory consultancy is key in ensuring timely patient access to safe and effective medicines. Companies like PharmDedict bridge pharma manufacturers and regulatory authorities, supporting efficient assessments and authorizations. What are your thoughts on how the industry can further drive growth and innovation in Europe?

🚨 New Requirements for AMNOG Dossiers: What Pharma Companies Need to Know! 🚨 The recently enacted Medical Research Act introduces significant changes for submitting AMNOG dossiers: 👉 Starting January 2025, pharmaceutical companies must demonstrate the number of study participants in their clinical trials recruited at sites located in Germany (within the SGB V jurisdiction). The threshold number in order to apply for the price railguard waver is 5%! 📝 Updated Dossier Template (Module 3): The Federal Joint Committee (G-BA) has updated its procedural rules to include new documentation requirements: Section 3.6 & Table 3.11: Detailed reporting of participant recruitment by country and study site. Consideration of all relevant studies listed in the dossier, including those already submitted during the marketing authorization process. 💡 Transitional Provisions: Until the new template is officially released, pharmaceutical companies can continue using the current version, supplemented with the new Section 3.6 and Table 3.11 as an interim solution. 📌 These changes will be evaluated as part of the benefit assessment process starting in January 2025. The G-BA will provide the finalized template and further guidance in due course. ➡️ Pharmaceutical companies should start preparing now to ensure compliance with these new requirements. Contact us! [email protected] #AMNOG #BenefitAssessment #MedicalResearchAct #Pharma #GBA

As a pivotal player in the global pharmaceutical industry, India is showcasing its prowess in innovation and development, delivering significant value to patients around the world. Fortrea is holding two face-to-face sessions in India with senior executive leaders from across India’s pharmaceutical industry. Share your insights on the latest advancements in data science and technology, explore new partnership models, and contribute to setting the blueprint for the future of both India’s pharmaceutical sector and the global healthcare ecosystem. Contact [email protected] if you are interested in joining one of two sessions. #ClinicalResearch #PharmaceuticalInnovation #GlobalHealthcare #IndiaPharma #HealthcareLeadership #PartnershipModels #HealthcareEcosystem

As a pivotal player in the global pharmaceutical industry, India is showcasing its prowess in innovation and development, delivering significant value to patients around the world. Fortrea is holding two face-to-face sessions in India with senior executive leaders from across India’s pharmaceutical industry. Share your insights on the latest advancements in data science and technology, explore new partnership models, and contribute to setting the blueprint for the future of both India’s pharmaceutical sector and the global healthcare ecosystem. Contact [email protected] if you are interested in joining one of two sessions. #ClinicalResearch #PharmaceuticalInnovation #GlobalHealthcare #IndiaPharma #HealthcareLeadership #PartnershipModels #HealthcareEcosystem

As a pivotal player in the global pharmaceutical industry, India is showcasing its prowess in innovation and development, delivering significant value to patients around the world. Fortrea is holding two face-to-face sessions in India with senior executive leaders from across India’s pharmaceutical industry. Share your insights on the latest advancements in data science and technology, explore new partnership models, and contribute to setting the blueprint for the future of both India’s pharmaceutical sector and the global healthcare ecosystem. Contact [email protected] if you are interested in joining one of two sessions. #ClinicalResearch #PharmaceuticalInnovation #GlobalHealthcare #IndiaPharma #HealthcareLeadership #PartnershipModels #HealthcareEcosystem

As a pivotal player in the global pharmaceutical industry, India is showcasing its prowess in innovation and development, delivering significant value to patients around the world. Fortrea is holding two face-to-face sessions in India with senior executive leaders from across India’s pharmaceutical industry. Share your insights on the latest advancements in data science and technology, explore new partnership models, and contribute to setting the blueprint for the future of both India’s pharmaceutical sector and the global healthcare ecosystem. Contact [email protected] if you are interested in joining one of two sessions. #ClinicalResearch #PharmaceuticalInnovation #GlobalHealthcare #IndiaPharma #HealthcareLeadership #PartnershipModels #HealthcareEcosystem

As a pivotal player in the global pharmaceutical industry, India is showcasing its prowess in innovation and development, delivering significant value to patients around the world. Fortrea is holding two face-to-face sessions in India with senior executive leaders from across India’s pharmaceutical industry. Share your insights on the latest advancements in data science and technology, explore new partnership models, and contribute to setting the blueprint for the future of both India’s pharmaceutical sector and the global healthcare ecosystem. Contact [email protected] if you are interested in joining one of two sessions. #ClinicalResearch #PharmaceuticalInnovation #GlobalHealthcare #IndiaPharma #HealthcareLeadership #PartnershipModels #HealthcareEcosystem

As a pivotal player in the global pharmaceutical industry, India is showcasing its prowess in innovation and development, delivering significant value to patients around the world. Fortrea is holding two face-to-face sessions in India with senior executive leaders from across India’s pharmaceutical industry. Share your insights on the latest advancements in data science and technology, explore new partnership models, and contribute to setting the blueprint for the future of both India’s pharmaceutical sector and the global healthcare ecosystem. Contact [email protected] if you are interested in joining one of two sessions. #ClinicalResearch #PharmaceuticalInnovation #GlobalHealthcare #IndiaPharma #HealthcareLeadership #PartnershipModels #HealthcareEcosystem

As a pivotal player in the global pharmaceutical industry, India is showcasing its prowess in innovation and development, delivering significant value to patients around the world. Fortrea is holding two face-to-face sessions in India with senior executive leaders from across India’s pharmaceutical industry. Share your insights on the latest advancements in data science and technology, explore new partnership models, and contribute to setting the blueprint for the future of both India’s pharmaceutical sector and the global healthcare ecosystem. Contact [email protected] if you are interested in joining one of two sessions. #ClinicalResearch #PharmaceuticalInnovation #GlobalHealthcare #IndiaPharma #HealthcareLeadership #PartnershipModels #HealthcareEcosystem